Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Liwanli Innovation Co's Enterprise Value is NT$3,863.2 Mil.
Liwanli Innovation Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was NT$149.8 Mil. Therefore, Liwanli Innovation Co's EV-to-FCF for today is 25.78.
The historical rank and industry rank for Liwanli Innovation Co's EV-to-FCF or its related term are showing as below:
TPE:3054'
s EV-to-FCF Range Over the Past 10 Years
Min: -136.03 Med: -8.75 Max: 1067.84
Current: 25.78
During the past 13 years, the highest EV-to-FCF of Liwanli Innovation Co was 1067.84. The lowest was -136.03. And the median was -8.75.
TPE:3054's EV-to-FCF is ranked worse than 55.28% of 559
companies
in the Drug Manufacturers industry
Industry Median: 20.58
vs TPE:3054: 25.78
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Liwanli Innovation Co (TPE:3054) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Liwanli Innovation Co's PE Ratio (TTM) for today is calculated as:
Liwanli Innovation Co's share price for today is NT$56.70.
Liwanli Innovation Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$4.820.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Liwanli Innovation Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Liwanli Innovation Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Liwanli Innovation Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Liwanli Innovation Co's EV-to-FCF falls into.
Liwanli Innovation Co's current Enterprise Value is NT$3,863.2 Mil.
Liwanli Innovation Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$149.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liwanli Innovation Co (TPE:3054) has a EV-to-FCF of 25.78 as of Aug. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Liwanli Innovation Co and its competitors. According to the industry distribution chart, Liwanli Innovation Co ranks #309 out of 559 companies in the Drug Manufacturers industry, placing it in the top 55.3%.
Is Liwanli Innovation Co's EV-to-FCF too high?
Liwanli Innovation Co's current EV-to-FCF is 25.78. The Drug Manufacturers industry median EV-to-FCF is 20.58. Liwanli Innovation Co's value of 25.78 is 25.3% above this industry median. Based on the distribution chart, Liwanli Innovation Co ranks #309 out of 559 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Liwanli Innovation Co has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Liwanli Innovation Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Liwanli Innovation Co ranks #309 out of 559 companies for EV-to-FCF. This places Liwanli Innovation Co in the lower half of its industry. The industry median EV-to-FCF is 20.58. Liwanli Innovation Co's value of 25.78 is 25.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.58, based on 559 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Liwanli Innovation Co's current EV-to-FCF of 25.78 is 25.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Liwanli Innovation Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liwanli Innovation Co's current EV-to-FCF is 25.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liwanli Innovation Co stock overvalued right now?
Based on GuruFocus' analysis, Liwanli Innovation Co (TPE:3054) is currently considered Possible Value Trap. The stock's GF Value™ is NT$119.56, compared to a current price of NT$56.70 — trading 52.6% below its estimated fair value. The current EV-to-FCF is 25.78 and 25.3% above the Drug Manufacturers industry median of 20.58. Liwanli Innovation Co's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Liwanli Innovation Co (TPE:3054), the current EV-to-FCF is 25.78 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Liwanli Innovation Co (TPE:3054) Overvalued in 2026?
Based on GuruFocus' analysis, Liwanli Innovation Co stock appears to be undervalued.
The current stock price of NT$56.70 is trading 52.6% below its estimated GF Value™ of NT$119.56.
GuruFocus considers Liwanli Innovation Co to be Possible Value Trap.
Key valuation signals for TPE:3054:
EV-to-FCF: 25.78
GF Value™: NT$119.56 vs. price of NT$56.70 (52.6% below fair value)
Industry Position: 25.3% above the Drug Manufacturers median (#309 of 559)
No single metric tells the full story. See the TPE:3054 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Liwanli Innovation Co Ltd is engaged in the manufacture, wholesale, and retail of electronic materials and the sales of biotech products like drug nutrient products. The reportable segments of the company are distinguished by products; the electronic department is mainly engaged in the sale and after-sales service of computer peripherals, memory and other related products; and the biotechnology department is mainly engaged in the sales of biotechnology products. Maximum revenue is generated from its Electronics department. Geographically, it generates a majority of its revenue from Taiwan, followed by other regions.
62GF Score
Get the complete analysis for TPE:3054
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:3054 has been successfully added to your 
